0001209191-18-011324.txt : 20180220 0001209191-18-011324.hdr.sgml : 20180220 20180220162156 ACCESSION NUMBER: 0001209191-18-011324 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180215 FILED AS OF DATE: 20180220 DATE AS OF CHANGE: 20180220 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Primiano Christopher Brett CENTRAL INDEX KEY: 0001603510 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36167 FILM NUMBER: 18624895 MAIL ADDRESS: STREET 1: C/O KARYOPHARM THERAPEUTICS INC. STREET 2: 85 WELLS AVENUE, SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Karyopharm Therapeutics Inc. CENTRAL INDEX KEY: 0001503802 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263931704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 85 WELLS AVENUE STREET 2: SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 BUSINESS PHONE: 617-658-0600 MAIL ADDRESS: STREET 1: 85 WELLS AVENUE STREET 2: SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-02-15 0 0001503802 Karyopharm Therapeutics Inc. KPTI 0001603510 Primiano Christopher Brett C/O KARYOPHARM THERAPEUTICS INC. 85 WELLS AVENUE NEWTON MA 02459 0 1 0 0 EVP, CBO, GC & Secretary Common Stock 2018-02-15 4 S 0 1014 15.0187 D 8867 D Common Stock 2018-02-16 4 S 0 1486 15.0054 D 7381 D This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.04, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each price. Represents the weighted average sale price. These shares were sold in transactions at $15.00 and $15.08. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each price. /s/Christopher B. Primiano 2018-02-20